9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences
- Stocks slip off record highs ahead of earnings, U.S. data
- Microsoft (MSFT) Near Deal to Acquire Nuance (NUAN) - Report
- Alibaba (BABA) Gets a Record $2.8 Billion Anti-Monopoly Fine, Shares Soar as a 'Major Overhang' is Lifted
- Tesla (TSLA) Upgraded to 'Buy' at Canaccord Genuity and PT Raised by 155%, as it 'Holds a Several-Year Lead' in EV While Storage Business Accelerates
- Dollar bounces higher as traders brace for inflation data
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
- Oppenheimer 31st Annual Healthcare Conference -
March 16th - 18th
- Maxim Group 2021 Emerging Growth Virtual Conference -
March 17th - 18th
RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that management will participate in the following conferences in the month of March and invites investors to participate by webcast or one-on-one meetings. Please see additional details below:
Oppenheimer 31st Annual Healthcare Conference
Title: 9 Meters Biopharma (NMTR) Company Presentation
Date: Wednesday, March 17, 2021
Time: 8:00 - 8:30 AM (ET)
Presenter: John Temperato, President & CEO
M Vest and Maxim Group 2021 Emerging Growth Virtual Conference
Title: 9 Meters Biopharma (NMTR)
Date: On demand presentation
Presenter: John Temperato, President & CEO
If you are interested in arranging a one-on-one meeting, please contact your bank conference representative or contact Corey Davis at LifeSciAdvisors.
For more information about the Oppenheimer 31st Annual Healthcare Conference, please refer to the conference website at the Oppenheimer & Co Events Link here.
For more information about and access to the 2021 Emerging Growth Virtual Conference, please refer to the conference website at the M-Vest Link here.
About 9 Meters Biopharma
9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended September 30, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Amy Jobe, Ph.D.
LifeSci Communications, LLC
Corey Davis, Ph.D.
LifeSci Advisors, LLC
SOURCE: 9 Meters Biopharma
View source version on accesswire.com:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 9 Meters Biopharma (NMTR) and Celiac Disease Foundation Report Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
- Amyris (AMRS) Prices $300M Public Offering (Secondary and Primary) of Common Stock at $15.75/sh
- 9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
Create E-mail Alert Related CategoriesAccesswire, Press Releases
Related EntitiesTwitter, Maxim Group, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!